SAN FRANCISCO (GenomeWeb) – Guardant Health plans to launch a research-use only version of a liquid biopsy assay for cancer recurrence monitoring later this month, CEO Helmy Eltoukhy said at the Business in Personalized Medicine Summit in Millbrae, California last week.
During a presentation at the meeting, Eltoukhy provided an update on the firm's program to develop cell-free DNA assays for cancer recurrence monitoring and early detection.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
